Overview

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2017-03-15
Target enrollment:
Participant gender:
Summary
This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive. Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.
Phase:
Phase 2
Details
Lead Sponsor:
Oramed, Ltd.
Collaborator:
Integrium
Treatments:
Insulin
Insulin, Globin Zinc